Metropolis Healthcare Limited has provided a business update for Q3FY25, showcasing strong performance despite a seasonally lean period for diagnostic companies, especially in the West and South regions. The key highlights of the update are as follows:
- Revenue Growth: The company achieved an approximate 11% year-on-year growth in revenue, driven by increases in patient volumes, test volumes, and realization benefits.
- Segment Performance:
- B2C Segment: Revenue surged by approximately 15% YoY due to the company’s industry-leading testing capabilities and strong brand appeal. A price hike is being considered in select cities for Q4FY25.
- B2B Segment: Recorded low double-digit growth, though overall growth was partially impacted by a decline in the institutional business.
- Truhealth Wellness & Bundling: Emerged as the fastest-growing category with a remarkable 25% YoY growth.
- Financial Position: The company remains debt-free with cash reserves of approximately ₹200 crores as of December 31, 2024.
- Outlook: Metropolis is optimistic about revenue growth and margin expansion, with an openness to inorganic opportunities to drive further growth.
The financial results for Q3FY25 are yet to be approved by the Board of Directors and reviewed by auditors.
TOPICS:
Metropolis Healthcare